Professor Andrew Wilks

Professor Andrew Wilks

FTSE FAHMS

Executive Chairman at SYNthesis med chem, CEO at SYNthesis Research, CEO at Catalyst Tx
SYNthesis Research
Fellow
Elected in 2020
VIC
Citation on election

Professor Andrew Wilks is an accomplished academic scientist who worked at the LICR (Melbourne) between 1983 and 1997 and made transformative discoveries in the signal transduction field, as well as in neurogenesis and angiogenesis. He has completed a rare ‘trifecta’ – discovering and patenting a number of important drug discovery targets (e.g. JAK1 and JAK2); founding one of Australia’s most successful biotech companies, Cytopia; and co‐inventing and leading the team that delivered the JAK inhibitor, Momelotinib.

Co‐founder and CEO of the SYNthesis Group, Professor Wilks is a serial entrepreneur and founder or co‐founder of ten companies in the drug discovery arena

Find out more

Whether you’re looking to nominate a colleague for an award, make a donation to the Academy or simply find out more about the work we do, research we advance and health policy advice we provide, sign up to our mailing list today.

Keep up to date with the latest news

By providing your email address, you consent to it being added to our mailing list.